

Substitute for form 1449A/PTO		COMPLETED BY [REDACTED] 08 OCT 2004	
INFORMATION DISCLOSURE			
STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	1	of	4
		Application Number	
		Filing Date	
		First Named Inventor	Flores, Osvaldo A. et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	21080P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Zachariah Lucas/	Date Considered	06/26/2007
-----------------------	-------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DRAFT POC 10 08 OCT 2004

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	07510912
				Filing Date	
				First Named Inventor	Flores, Osvaldo A. et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	
21080P					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/ZL		Alter, H. "To C or Not To C: These Are the Questions", Blood, 1995, Vol. 85, pp. 1681-1695			
		Ambler, R. "The structure of β-lactamases", Phil. Trans. R. Soc. Lond. B. Biol. Sci., 1980, Vol. 289, pp. 321-331			
		Bartenschlager, R. et al. "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions", Journal of Virology, 1993, Vol. 67, pp. 3835-3844			
		Behrens, S. et al. "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus", The EMBO Journal, 1996, Vol. 15, pp. 12-22			
		Blight, K. et al. "Efficient Initiation of HCV RNA Replication in Cell Culture", Science, 2000, Vol. 290, pp. 1972-1974			
		Castelain, S. et al. "Variability of the Nonstructural 5A Protein of Hepatitis C Virus Type 3a Isolates and Relation to Interferon Sensitivity", The Journal of Infectious Diseases, 2002, Vol. 185, pp. 573-583			
		Chamberlain, R. et al. "Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East", Journal of General Virology, 1997, Vol. 78, pp. 1341-1347			
		Choo, Q. et al. "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome", Science, 1989, Vol. 244, pp. 359-262			
		De Francesco, R. et al. "Biochemical and Immunologic Properties of the Nonstructural Proteins of the Hepatitis C Virus: Implications for Development of Antiviral Agents and Vaccines", Seminars in Liver Disease, 2000, Vol. 20, pp. 69-83			
		Failla, C. et al. "Both NS3 and NS4A Are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins", Journal of Virology, 1994, Vol. 68, pp. 3753-3760			
		Farci, P. et al. "Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome", Proc. Natl. Acad. Sci. USA, 2002, Vol. 99, pp. 3081-3086			
		Grahovac, B. et al. "Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C", Journal of Clinical Virology, 2001, Vol. 20, pp. 85-89			
		Grakoui, A. et al. "A second hepatitis C virus-encoded proteinase", Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, pp. 10583-10587			
		Grakoui, A. et al. "Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products", Journal of Virology, 1993, Vol. 67, pp. 1385-1395			
/ZL		Hijikata, M. et al. "Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus", Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, pp. 10773-10777			

Examiner Signature	/Zachariah Lucas/	Date Considered	06/26/2007
--------------------	-------------------	-----------------	------------

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN 107510912	
Sheet	3	of	4	Attorney Docket Number	21080P

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/ZL/		Honda, M. et al. "Structural Requirements for Initiation of Translation by Internal Ribosome Entry within Genome-Length Hepatitis C Virus RNA", Virology, 1996, Vol. 222, pp. 31-42			
		Iwarson, S. "The natural course of chronic hepatitis C", FEMS Microbiology Reviews, 1994, Vol. 14, pp. 201-204			
		Kadonaga, J. et al. "The Role of the β -Lactamase Signal Sequence in the Secretion of Proteins by <i>Escherichia coli</i> ", The Journal of Biological Chemistry, 1984, Vol. 259, pp. 2149-2154			
		Kew, M. "Hepatitis C virus and hepatocellular carcinoma", FEMS Microbiology Reviews, 1994, Vol. 14, pp. 211-219			
		Kolykhalov, A. et al. "Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3' Nontranslated Region Are Essential for Virus Replication In Vivo", Journal of Virology, 2000, Vol. 74, pp. 2046-2051			
		Kolykhalov, A. et al. "Identification of a Highly Conserved Sequence Element at the 3' Terminus of Hepatitis C Virus Genome RNA", Journal of Virology, 1996, Vol. 70, pp. 3363-3371			
		Kuo, G. et al. "An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis", Science, 1989, Vol. 244, pp. 362-364			
		Lohmann, V. et al. "Biochemical and Kinetic Analyses of NS5B RNA-Dependent RNA Polymerase of the Hepatitis C Virus", Virology, 1998, Vol. 249, pp. 108-118			
		Lohmann, V. et al. "Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation", Journal of Virology, 2001, Vol. 75, pp. 1437-1449			
		Lohmann, V. et al. "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line", Science, 1999, Vol. 285, pp. 110-113			
		Mizushima, H. et al. "Analysis of N-Terminal Processing of Hepatitis C Virus Nonstructural Protein 2", Journal of Virology, 1994, Vol. 68, pp. 2731-2734			
		Pawlotsky, J. "Hepatitis C virus (HCV) NSSA protein: role in HCV replication and resistance to interferon- α ", Journal of Viral Hepatitis, 1999, Vol. 6, Suppl. 1, pp. 47-48			
		Pietschmann, T. et al. "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs", Journal of Virology, 2001, Vol. 75, pp. 1252-1264			
		Simmonds, P. "The origin and evolution of hepatitis viruses in humans", Journal of General Virology, 2001, Vol. 82, pp. 693-712			
/ZL/		Takamizawa, A. et al. "Structure and Organization of the Hepatitis C Virus Genome Isolated from Human Carriers", Journal of Virology, 1991, Vol. 65, pp. 1105-1113			

Examiner Signature	/Zachariah Lucas/	Date Considered	06/26/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary).

Sheet 4 of 4 Attorney Docket Number 21080P

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Zachariah Lucas/	Date Considered	06/26/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

240

1

of

2

Attorney Docket Number

21080P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

/Zachariah Lucas/

Date Considered

06/26/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2000

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number 21080P

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Zachariah Lucas/	Date Considered	06/26/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/200